Navigation Links
Novel therapy may prove effective in treatment of 30 percent of cancers
Date:5/13/2009

A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.

The study, inspired by the exciting discoveries made by Dr. Borden at IRIC, was a joint project between her research group, who monitored molecular events in trial patients, and Dr. Sarit Assouline of the Segal Cancer Centre, Jewish General Hospital, who led the clinical part of the trial.

The integration of these two teams made it possible to rapidly move from a research lab to patient tests. The study team targeted the gene by giving trial participants a mimic of its natural target, ribavirin. "Our results are the first to show that targeting eIF4E in humans is clinically beneficial," explains Dr. Borden. "We also found that ribavirin not only blocks eIF4E, it has no side effect on patients."

The trial studied patients with M4/M5 acute myeloid leukemia who had undergone several other treatments that had previously failed. "We had striking clinical improvements with even partial and complete remissions," indicated Assouline.

Dr. Wilson Miller, director of the Clinical Research Unit, Jewish General Hospital, and co-investigator in the trial added: "It's rare that discoveries in basic research move to clinical so quickly and successfully."

The next challenge for this team is to overcome the resistance that develops over time to ribavirin. "Combination therapy with chemotherapeutic agents may enhance the efficacy of this treatment," explains Borden, "Trials in the near future are planned to overcome this and we are looking forward to more complete remissions. We also hope to test whether ribavirin is as effective in the treatment of other cancers with dysregulated eIF4E. Our laboratory studies suggest this is likely."

The study team also included Drs. Brian Leber from McMaster University/Hamilton Health Sciences (Ontario) and Denis-Claude Roy from Hpital Maisonneuve-Rosemont in Montreal. The study was made possible thanks to a $600,000 grant awarded to Dr. Borden by The Leukemia and Lymphoma Society (USA).


'/>"/>

Contact: Carolyne Lord
carolyne.lord@umontreal.ca
514-343-7282
University of Montreal
Source:Eurekalert

Related medicine news :

1. Telesso Technologies wins Popular Science Invention Award for its novel peripheral IV catheter
2. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
3. Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide
4. Novel gene predicts local recurrence in early onset breast cancer
5. Novel gene predicts local recurrence in early-onset breast cancer
6. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
7. Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions
8. Compendia Bioscience Announces Collaboration with MDS Pharma Services to Deliver Novel Solution for Oncology Drug Development
9. Spiritual Leaders Teachings Collected in New Novel
10. Novel role of protein in generating amyloid-beta peptide
11. Novel cancer drug reduces neuroblastoma growth by 75 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... Houma, LA, celebrates the beginning of a new charity campaign. As part of ... Appointed Special Advocates (CASA). In the belief that children deserve a voice, and ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... If you ... much to handle, you are not alone. According to the Center for Disease Control ... disease, stroke, type 2 diabetes and certain types of cancer, some of the leading ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... program serving the greater Venice, FL area, has initiated a fundraiser for a ... car accident just four days after Christmas. To support this beautiful child who ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic ... of women and men with eating disorders report a history of trauma, research ... development of an eating disorder. , At the 2016 iaedp Symposium, the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of ... AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are working closely ... coding guidance and clarifications, to address concerns over the use of 'A' as ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  HemaFlo Therapeutics, Inc. announced today that ... US Patent Number 9,119,880 covering the use of NephroFlow to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s ...
(Date:2/8/2016)... Feb. 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... editing, announced that the U.S. Food and Drug ... Drug (IND) application for SB-318, a single treatment ... Mucopolysaccharidosis Type I (MPS I). The SB-318 IND ... initiate a Phase 1/2 clinical study (SB-318-1502) designed ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, ... heute eine Infografik mit dem Titel „Epilepsy ... Welt), mit der der Krankheit gegenüber ein ... dazu ermutigen soll, Medikamentenresistenz bei Epilepsie auf ... allgemeinen Diskussion zu machen. Mithilfe der neuen ...
Breaking Medicine Technology: